Dr. Lena Thin - Biosimilar Hub

Dr. Lena Thin

Claim this profile

Fiona Stanley Hospital

Studies Crohn's Disease
Studies Colitis
6 reported clinical trials
6 drugs studied

Clinical Trials Lena Thin is currently running

Image of trial facility.

TAK-279

for Ulcerative Colitis

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.
Recruiting0 awards Phase 21 criteria
Image of trial facility.

Vedolizumab

for Crohn's Disease

Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ultrasound (IUS), a patient-friendly technique that can be performed routinely in clinical practice. The aim of the study is to determine if treating to a target of corticosteroid-free (CS-free) IUS outcomes + clinical symptoms + biomarkers is superior to a target of clinical symptoms + biomarkers alone in achieving CS-free endoscopic remission measured by the Simple Endoscopic Score for Crohn's Disease (SES-CD). Qualified participants will be randomly assigned in a 1:1 ratio to one of 2 different target treatment groups. Group 1: Participants will be treated over 48 weeks to achieve a target of corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission. At Week 22 and 30, the IUS-based component of the target will be IUS response and at Week 38, the final treatment target will be TMH. Group 2: Participants will be treated over 48 weeks to achieve a target of corticosteroid-free clinical remission + biomarker remission.
Recruiting3 awards Phase 43 criteria

More about Lena Thin

Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Lena Thin has experience with
  • Mirikizumab
  • No Treatment
  • Vedolizumab
  • TAK-279
  • BMS-986165
  • Placebo

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Lena Thin specialize in?
Is Lena Thin currently recruiting for clinical trials?
Are there any treatments that Lena Thin has studied deeply?
What is the best way to schedule an appointment with Lena Thin?
What is the office address of Lena Thin?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security